Your specialists for health, pharmaceutical & medical device law


kaltwasser rechtsanwälte –
the law firm

The firm is a full-service provider for pharmaceutical companies. In addition to advising and litigating on drug advertising law / competition law, we are extensively active in the areas of medicinal product law, sponsoring (cooperation between the pharmaceutical industry and third parties), the planning and implementation of clinical trials, social law issues arising in the pharmaceutical sector and liability law. We also advise pharmaceutical companies on employment law.

focal points

  • // Scientific validation – with and without gold standard

    // Differentiation between product & image advertising

    // Mandatory information

    // Advertising in the package leaflet / on the outer packaging

    // Pre- & post-marketing

    // Customer relationship systems (CRM) in the healthcare sector

    We offer:

    // Consulting

    // Representation in warning letters and court proceedings (injunction, lawsuit)

    // Training for employees on & offsite

  • // Price regulation under the AMNOG

    // Early benefit assessment by the Federal Joint Committee (G-BA)

    // Reimbursement amount negotiations with the National Association of Statutory Health Insurance Funds (GKV-SV)

    // Discount agreements

    // Regional pharmaceutical contracts

    // Prescription control by associations of statutory health insurance physicians, health insurance funds & review bodies

    // Fixed amounts

    // Therapy notes

    // Prescription restrictions & exclusions

    // aut idem rule

    // Lead substance targets & quotas

    // Medication catalog of the KBV

    // Drug information system

    // Performance audit

    We offer:

    // Consulting

    // Representation vis-à-vis cost bearers, before (civil, social & administrative) courts & authorities (G-BA, GKV-SV, public procurement chambers)

  • // Authorization (original, hybrid medicinal products, generics, biosimilars)

    // Labeling (outer packaging, containers, product information, package leaflet)

    // distribution (distribution channels, co-promotion, co-marketing, co-distribution)

    // Legal requirements for pricing

    // In-house & contract manufacturing

    // responsible persons (step-by-step plan & information officer)

    // Manufacturing & wholesale authorization

    // Delimitation of responsibility contracts

    // Reimbursement (SGB V)

    // Research & development contracts (see "Clinical studies")

    // Drug safety (pharmacovigilance)

    We offer:

    // Consulting

    // Representation before authorities & courts

    // Training for employees on & offsite

  • // Classification (for apps & software or differentiation from medicinal products)

    // Conformity assessment

    // Placing on the market (CE marking)

    // Product information (labeling & instructions for use)

    // Contract manufacturing, distribution, contracts

    // Liability

    We offer:

    // Consulting

    // Representation before authorities & courts

    // Training for employees on & offsite

  • // Cooperation with HCPs, medical facilities (outpatient & inpatient), pharmacies

    // Cooperations, sponsoring, speaker contracts

    // Anti-corruption law, 299a/b StGB & industry codes (FSA, AKG, BVMed, EFPIA...)

    We offer:

    // Consulting

    // Preparation & implementation of SOPs

    // Representation before courts & self-help organizations

    // Training for employees on & offsite

  • // Research & development contracts

    // Funding & cooperation agreements for ISS ("Investigator Sponsored Study" = IIS)

    // Investigator contracts

    // CRO contracts

    // Manufacturing, labeling & reimbursement of investigational medicinal products

    We offer:

    // Consulting

    // Representation before courts, (regulatory) authorities & ethics committees

  • // Product liability claims of patients for medicinal products & medical devices

    // Claims for information, in particular for medicinal products according to § 84a AMG

    // Product recalls

    We offer:

    // Consulting

    // Representation vis-à-vis claimants (patients) & in court

    // Training for employees on & offsite

  • // Professional law

    // Effects of the Anti-Corruption Act

    // Pharmacy operating regulations

    // Multiple ownership & mail order

    // Hospital supply

    // Wholesale license

    // Inspections

    We offer:

    // Consulting

    // Representation vis-à-vis payers, before courts & authorities

LAWYERS

Kaltwasser Rechtsanwälte – Dr. Jan-Tobias Häser
Kaltwasser Rechtsanwälte – Rainer Cornet

  • PARTNER

    Areas of specialization

    Competition law,
    drug advertising law,
    pharmaceutical law,
    private construction law,
    labor law

    Admission
    Lawyer since 1990

    Languages
    German, English, French, Italian, Spanish

Kaltwasser Rechtsanwälte – Dr. Friederike Hartwein

recommendations

Awards in Handelsblatt / Best Law Firms

Deutschlands BESTE Kanzleien 2025

Awards in Handelsblatt / Best Lawyers

Deutschlands BESTE Anwälte 2020 – 2025

  • “In addition to its focus on litigation, the firm also provides strategic advice on regulatory issues surrounding AMNOG/market access, reimbursements, and clinical trials. Kaltwasser also covers contract drafting, pharmaceutical liability, and healthcare compliance. The team regularly acts as an outsourced legal department for its clients, which primarily include medium-sized pharmaceutical companies, but also medical device manufacturers.

    strenghts: HWG & social court cases
    often recommended: Dr. Jan-Tobias Häser
    team: 2 partners, 1 associate

  • “The Munich law firm is primarily recognized for its work in HWG processes, but is also increasingly representing its client base from the pharmaceutical industry in social court proceedings. The lawyers also have experience with strategic questions, such as distribution. In pharmaceutical law, the BGH ruling on the granting of discounts by wholesalers to pharmacies recently created a need for advice. Here, the team advised on contract drafting.”

    strenghts: HWG court cases
    often recommended: Dr. Jan-Tobias Häser
    team: 2 partners, 1 associate

  • “The small Munich boutique is particularly renowned for its proven experience with HWG processes. The practice led by the busy Häser is increasingly representing its client base from the pharmaceutical industry in social court proceedings. In addition to litigation, strategic advice, for example on sales issues, takes up a lot of space. The team is increasingly acting as an outsourced legal department. The practice, which previously worked purely as a partnership, recently strengthened itself with the addition of an associate.”

    strenghts: HWG court cases
    often recommended: Dr. Jan-Tobias Häser
    team: 2 partners, 1 associate

lectures

  • “Skonti”

    03/2025 | Philips-University Marburg

    more information

  • 10/2025 | 09/2022 | 09/2021 | 09/2019 | 09/2018 | 09/2017
    University of Augsburg, Center for continuing education and knowledge transfer (ZWW)

    more information

  • 10/2025 | 09/2022 | 09/2021 | 09/2019 | 09/2018 | 09/2017 | 09/2016 | 09/2015
    University of Augsburg, Center for continuing education and knowledge transfer (ZWW)

    more information

  • 09/2022 | 09/2021 | 09/2019 | 09/2018 | 09/2017 | 09/2016
    University of Augsburg, Center for continuing education and knowledge transfer (ZWW)

    more information

  • “Drug information from health insurance companies, KVs or testing committees – regional control and central decision-making”

    03/2018 | Philips-University Marburg

    more information

  • “Advertising for medical devices with study results”

    10/2016 | Faculty of Law at the University of Augsburg

  • “Drug advertising with studies without a gold standard”

    03/2018 | Philips-University Marburg

    mehr Information

  • “Advertising with study results”

    03/2014 | Philips-University Marburg

    mehr Information

PUBLICATIONS

  • Häser
    Bevorzugte Verordnung zuzahlungsbefreiter Arzneimittel – Geltung des Wirtschaftlichkeitsgebots auch zugunsten der Patientinnen und Patienten
    PharmR 2025, 792

  • Häser
    Preisrecht und Erstattungsrecht – Skonti
    PharmR 2025, 214

  • Hartwein
    Straftatbestände in Deutschland im zeitgeschichtlichen Kontext
    (Dissertation), Schriftenreihe Studien zur Rechtswissenschaft, Hamburg 2023, ISBN 978-3-339-13386-1

  • Sonder/von Beauvais/Hartwein
    Ein Jahr nach dem Telekommunikationsmodernisierungsgesetz – Erste Erfahrungen aus der Praxis
    MMR-Aktuell 2023, 457186

  • Häser
    Arzneimittelinformationen von Krankenkassen, KVen oder Prüfgremien – Regionale Steuerung und zentrale Entscheidung
    in Voit, "Werberecht und Absatzförderung/Preisrecht" aus der Reihe "Marburger Schriften zum Gesundheitswesen", Band 31, 1. Auflage 2019, dort S. 25 ff.

  • Häser
    Arzneimittelwerbung mit Studien ohne Goldstandard
    in: Voit, "Transparenz/Neue Produkte" aus der Reihe "Marburger Schriften zum Gesundheitswesen", Band 29, 1. Auflage 2017, dort S. 307 ff.

  • Häser
    Werbung mit Studienergebnissen
    in: Voit, "Marktzugang unter den Bedingungen des AMNOG – Werbung auf dem Markt" aus der Reihe "Marburger Schriften zum Gesundheitswesen", Band 24, 1. Auflage 2016, dort S. 123 ff.

  • Häser
    Haftpflichtversicherungsschutz angestellter Krankenhausärzte
    (Dissertation), Schriftenreihe arbeitsrechtliche Forschungsergebnisse, Hamburg 2001, ISBN 3-8300-0603-9

contact us

KALTWASSER Rechtsanwälte
Maximiliansplatz 17
D–80333 Munich


Tel. +49 / 89 / 210 230-0
Fax +49 / 89 / 210 230-30


info@kcsf.de